Nearly 4 Billion-Dollar Market for IVD Packaging

Nearly 4 Billion-Dollar Market for IVD Packaging

In vitro diagnostic tests require specialized boxes, bottles, bags and plates to protects crucial chemicals and insure a quality result each time a test is performed. Thus it’s not surprising that growth in IVD drives growth in packaging. That’s the conclusion of The Freedonia Group’s new study, In Vitro Diagnostic Test Packaging. Take two trends for example. The increasing use of point-of-care tests and the development of high-quality molecular testing supplies. Both trends drive more and highe...


Direct-to-Consumer Services Put Down Roots in U.S. Lab Testing Market

Direct-to-Consumer Services Put Down Roots in U.S. Lab Testing Market

Still framed as an open proposition in healthcare, the direct-to-consumer (DTC) lab testing market has already captured robust demand from U.S. consumers. Sales of DTC testing services have rapidly grown outside the traditional paradigm of physician-facilitated clinical testing. Kalorama Information’s Direct-to-Consumer Laboratory Testing Market has served as an important reference in recent articles by the New York Times, Forbes, and Becker’s Hospital Review. Whereas media coverage has focused ...


Luminex Acquisition of Nanosphere Continues Trend of Investment in Decentralized Molecular Testing

Luminex Acquisition of Nanosphere Continues Trend of Investment in Decentralized Molecular Testing

This blog post reviews the recent history of acquisitions and investment in the area of decentralized molecular diagnostics. Kalorama Information’s The Market and Potential for Molecular Point of Care Diagnostics provides the current market, projected future sales and total available markets in 2020 for molecular POC diagnostics for flu, strep A, RSV, CT/NG, group B strep (GBS), HPV, HSV, vaginitis, HIV, TB, hepatitis, malaria and many other disease areas.

On May 16, Luminex Corporation announ...


miRNA Tools Lead Development of Next-Generation Therapeutics and Diagnostics

miRNA Tools Lead Development of Next-Generation Therapeutics and Diagnostics

Although microRNAs (miRNAs) represent only a small fraction of the total RNA mass in a given sample - estimated at about 0.01% - the short RNA molecules (16-35 nucleotides) are widely viewed as a rich analytical resource for biomarkers and drug targets. miRNAs are believed to be involved in the regulation of more than 30% of protein-coding human genes through a complex regulatory network. Through broad gene regulation activity, miRNAs influence a range of cell processes and consequently play rol...